跳至主要内容
临床试验/CTRI/2025/06/088719
CTRI/2025/06/088719尚未招募不适用

To study the effectiveness and safety of Topical Tretinoin 0.1% Cream in indications related to aging on Indian skin

H&H Pharmaceutica LLP1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年6月26日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
40
试验地点
1
主要终点
Change in wrinkle severity score (Modified Griffiths Scale or WSRS)

研究概览

简要总结

Skinaging is a complex and multifactorial biological process that leads to gradualdeterioration in the skin’s structure, function and appearance. Common clinicalmanifestations include fine lines, wrinkles, dyspigmentation, laxity, and lossof elasticity. This process is influenced by intrinsic (endogenous) factorssuch as genetics, cellular senescence, and hormonal changes, as well asextrinsic (exogenous) factors including ultraviolet (UV) radiation,environmental pollutants, and mechanical stress. These factors contribute tounderlying physiological changes like glycation, oxidative stress,inflammation, impaired DNA repair, and extracellular matrix degradation (Shinet al., 2023; Knaggs et al., 2023).

Topicalantiaging treatments have gained significant popularity in clinicaldermatology, with retinoids—particularly tretinoin—recognized as the goldstandard due to their proven efficacy in reducing fine lines, evening skintone, promoting collagen synthesis, and increasing epidermal turnover (Milosheska & Roskar, 2022; Sitohang etal., 2022).

Tretinoin, a derivative of vitamin A,penetrates the epidermis and binds to intracellular retinoic acid receptors(RARs). These receptors form heterodimers with retinoid X receptors (RXRs),which then bind to retinoic acid response elements (RAREs) in the DNA ofkeratinocytes and fibroblasts. This molecular interaction regulates thetranscription of various genes responsible for skin remodelling and repair.

Through this RAR–RXR–RARE signalling axis,tretinoin upregulates the expression of genes involved in collagen production,including procollagen I and III, thereby enhancing skin firmness and reducingwrinkles. It also boosts skin regeneration by promoting cellular turnover andsupports angiogenesis, which improves oxygen and nutrient delivery to the skin.Simultaneously, tretinoin downregulates processes contributing to photoaging,such as excessive keratinocyte proliferation, matrix metalloproteinases (MMPs)that degrade collagen, pro-inflammatory cytokines like IL-6 and TNF-alpha, andtyrosinase activity, which is involved in melanin synthesis and pigmentation.

The primary target cells of tretinoin arekeratinocytes in the epidermis and fibroblasts in the dermis. Keratinocytesinfluence epidermal thickness and renewal, while fibroblasts are central toextracellular matrix (ECM) maintenance, producing collagen and elastin. Bymodulating gene expression in both cell types, tretinoin not only stimulatescollagen synthesis and inhibits its degradation but also reduces inflammationand pigmentation, making it a fundamental agent in dermatologic anti-agingtreatment strategies (Uchida et al., 2003; Mambwe et al., 2025).

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
35.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • 1.Male or female subjects aged 35 to 70 years with visible signs of skin aging.
  • 2.Subjects having one or more signs of aging such as wrinkles, fine lines, uneven skin tone, or mild pigmentation.
  • 3.Subjects belonging to Fitzpatrick skin types III to V.
  • 4.Subjects willing and able to comply with the study protocol and abstain from any anti-aging treatments or topical medications (other than the investigational product) during the 16-week study period.
  • 5.Subjects must provide written informed consent prior to participation.
  • 6.If using make-up, subjects must have used the same brand/type for at least 14 days prior to study entry and agree not to change the product or usage frequency during the study.

排除标准

  • 1.Subjects with known hypersensitivity or allergy to tretinoin, retinoids, or any ingredients in the investigational product.
  • 2.Women who are pregnant, lactating, or planning pregnancy during the study period.
  • 3.Subjects with history of cosmetic or dermatologic procedures within 3 months prior to baseline (e.g., chemical peels, microdermabrasion).
  • 4.Subjects intended to use anti-aging products (topical or oral) other than investigation product during the study.
  • 6.Subjects having baseline irritation score of 3 (severe) based on investigator’s assessment.
  • 7.Subjects with history of use of oral retinoids within 6 months before baseline or planned use during the study.
  • 8.Subjects who used hormonal contraceptives within 3 months prior to baseline.
  • 9.Subjects undergone prior laser therapy or phototherapy within the past 6 months to study entry.
  • 10.Subjects who underwent cosmetic treatments (e.g., facials) within 14 days prior to study start that may influence study outcomes.
  • 11.Subjects who are current smokers or history of tobacco use exceeding 10 pack-years.
  • 12.Unstable, clinically significant, or life-threatening disease that may pose a risk to the subjects or affect the study results, as judged by the investigator.
  • 13.Subjects who are regular engagement in activities involving prolonged sun exposure or exposure to extreme weather conditions (e.g., wind, cold).
  • 14.Subjects who are engaged in alcohol consumption or use of recreational/abusive drugs (e.g., cannabinoids, cocaine, barbiturates).

结局指标

主要结局

Change in wrinkle severity score (Modified Griffiths Scale or WSRS)

时间窗: After 4 months

Improvement in skin texture (visual grading)

时间窗: After 4 months

次要结局

  • Wrinkle severity & photoaging grade were assessed using Antera 3D equipment.(Melanin & erythema levels were measured using Dermatcatch.)

研究者

发起方
H&H Pharmaceutica LLP
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验